Stephenson Cancer Center Physicians Introduce New Prostate Cancer Diagnosis Tool Leading To Better Patient Outcomes

Oklahoma men now have access to a powerful new solution for more targeted prostate biopsies at the Stephenson Cancer Center at the University of Oklahoma. 

Read more >
Shubham Pant, Md, Selected For Competitive Leadership Development Program With The American Society Of Clinical Oncology

Shubham Pant, MD, University of Oklahoma Associate Professor of Medicine, section of Hematology/Oncology, has been selected to participate in the 2015-2016 American Society of Clinical Oncology Leadership Development Program. Pant is a member of the Stephenson Cancer Center at OU.

Read more >
Undergraduate Students Participate in Cancer Research as Summer Research Scholars at the Stephenson Cancer Center

Ten undergraduate students are spending their summer working in cancer research laboratories at the Stephenson Cancer Center, located on the University of Oklahoma Health Sciences Center campus in Oklahoma City. Students are matched with cancer researchers at the Stephenson Cancer Center, including Danny Dhanasekaran, PhD, Deputy Director for Basic Research at the Center. The students participate in a variety of nationally funded research projects, including projects supported by the National Cancer Institute. 

Read more >
Oncologists At The Stephenson Cancer Center Present The Latest In Immunotherapy And Targeted Therapies At The American Society Of Clinical Oncology Annual Meeting

Oncologists from the Stephenson Cancer Center at the University of Oklahoma presented their latest research findings at the annual meeting of the American Society of Clinical Oncology, the premiere scientific meeting for clinical and translational oncology. 

Read more >
New Precision Medicine Trial at Stephenson Cancer Center Focuses on Patients Who Respond Exceptionally Well to a New Drug

To gain a better understanding of why some patients respond exceptionally well to an experimental drug while others do not, the Stephenson Cancer Center has launched a new precision medicine clinical trial sponsored by the National Cancer Institute.

The clinical trial is part of the National Cancer Institute’s new Exceptional Responders Initiative, which seeks to understand the molecular underpinnings of why some tumors respond exceptionally well to cancer treatment, especially chemotherapy. Exceptional responders are patients who have a unique response to treatments that are not effective for most other patients. 

Read more >